Len Lichtenfeld

Latest stories

4d
CBS News
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
CBS News / Posted 4 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
4d
CTV News
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
CTV News / Posted 4 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
4d
Newsmax
Immune Drug for Deadly Skin Cancer Extends Survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune Drug for Deadly Skin Cancer Extends Survival
Newsmax / Posted 4 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
Herald Sun
New melanoma drug boosts patient survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
New melanoma drug boosts patient survival
Herald Sun / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research was "a big... Read more
28 related stories
5d
Adelaide Now
New melanoma drug boosts patient survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
New melanoma drug boosts patient survival
Adelaide Now / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research was "a big... Read more
28 related stories
5d
The New Zealand Herald
Keytruda helping people survive years, not monthsmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Keytruda helping people survive years, not months
The New Zealand Herald / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
KHQ Spokane
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
KHQ Spokane / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
Your Hometown Lima Stations
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
Your Hometown Lima Stations / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
WDIO Duluth
Immune Drug for Deadly Skin Cancer Shows Long-Term Survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune Drug for Deadly Skin Cancer Shows Long-Term Survival
WDIO Duluth / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
KTVN Reno
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
KTVN Reno / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
KTRE Lufkin and Nacogdoches
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
KTRE Lufkin and Nacogdoches / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
WALB Albany
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
WALB Albany / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
KSWO Lawton-Wichita Falls
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
KSWO Lawton-Wichita Falls / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
WTVM 9 Columbus
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
WTVM 9 Columbus / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
The Seattle Times
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
The Seattle Times / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society’s deputy chief medical officer, said the new Keytruda research “is a big... Read more
28 related stories
5d
WSFA 12 Montgomery
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
WSFA 12 Montgomery / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories
5d
9&10 News Cadillac
Immune drug for deadly skin cancer shows long-term survivalmelanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while
Immune drug for deadly skin cancer shows long-term survival
9&10 News Cadillac / Posted 5 days ago
melanoma. The newest drug, Opdivo, targets the same protein as Keytruda, while Yervoy targets a different protein. Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer, said the new Keytruda research "is a big... Read more
28 related stories

People in this news